NCT06990152Completed
A Randomized, Double-blind Clinical Trial on the Efficacy of a Dietary Formulation Containing Medium-chain Triglycerides (MCT) and Fiber in Patients With Psoriatic Arthritis
Trial Clinico Randomizzato e Doppio-cieco Sull'Efficacia di Una Formulazione Alimentare Contenente Trigliceridi a Media Catena (MCT) e Fibre in Pazienti Con Artrite Psoriasica
Source: ClinicalTrials.gov · Last updated 20 Apr 2026
Brief summary (registry, in English)
The primary objective of this study is to evaluate the effects of a formulation containing medium-chain triglycerides (MCTs) and vegetable fibers on the quality of life of patients with psoriatic arthritis, by monitoring the patients over a period of 3 months in a single-center interventional study. As secondary objectives, the study will assess the effects of the same formulation on disease activity and on certain blood parameters and dietary habits.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 72 (actual)
- First submitted
- 9 May 2025
- Start date
- 16 May 2025
- Primary completion date
- 28 Feb 2026
- Lead sponsor
- Dr. Schär AG / SPA
- Diseases
- Psoriasis, Psoriatic arthritis
- NCT number
- NCT06990152
What you commit to
- Study type: Interventional
- Participants enrolled: 72
- From 16 May 2025 to the primary completion date, 28 Feb 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Disease activity in remission (DAPSA ≤ 4), moderate (14 \< DAPSA ≤ 28), or high (DAPSA \> 28) at the time of recruitment;
- Type 2 diabetes, cardiovascular diseases, hypertension, ischemic diseases, renal failure, malignant tumors, respiratory diseases, dyslipidemia, fibromyalgia, metabolic syndrome;
- Gastritis, esophagitis, reflux syndrome, chronic inflammatory bowel diseases (IBD);
Age
- Pediatric onset of the disease (\< 16 years);
Other
- BMI ≥ 27 kg/m²;
- Current or desired pregnancies (confirmed by pregnancy test);
- Patients on a vegan, ketogenic, or MCT-rich diet (containing MCT in supplement form or high amounts of palm or coconut oil);
- Presence of ketoacidosis/metabolic acidosis, decompensated liver cirrhosis, or medium-chain acyl-CoA dehydrogenase (MCAD) deficiency;
- Major depression;
- Lactose intolerance.
Who the study is looking for
- Adult patients: aged 18-80 years;
- Clinical diagnosis of PsA meeting the CASPAR classification criteria;
- Low disease activity (4 \< DAPSA ≤ 14) at the time of recruitment;
- Under stable pharmacological treatment with disease-modifying antirheumatic drugs (DMARDs) (conventional synthetic, targeted synthetic, or biological);
- Disease duration \> 6 months;
- Absence of metabolic diseases.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| ASST Gaetano Pini CTO, UOC Clinica Reumatologica Coordinator of this site? Confirm its status | Milan | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.